Cargando…
Skin barrier status during dupilumab treatment in patients with severe atopic dermatitis
BACKGROUND: Atopic dermatitis (AD) is a common chronic-relapsing inflammatory skin disease hallmarked by epidermal barrier dysfunction, increased transepidermal water loss (TEWL) and decreased skin hydration. Recent findings on the T helper 2 (Th2)-driven pathogenesis of AD have led to the developme...
Autores principales: | Ferrucci, Silvia, Romagnuolo, Maurizio, Maronese, Carlo Alberto, Germiniasi, Francesca, Tavecchio, Simona, Angileri, Luisa, Casazza, Giovanni, Marzano, Angelo Valerio, Genovese, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655442/ https://www.ncbi.nlm.nih.gov/pubmed/34900210 http://dx.doi.org/10.1177/20406223211058332 |
Ejemplares similares
-
Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience
por: Ferrucci, Silvia, et al.
Publicado: (2020) -
Efficacy of Dupilumab on Different Phenotypes of Atopic Dermatitis: One-Year Experience of 221 Patients
por: Tavecchio, Simona, et al.
Publicado: (2020) -
Predictive Factors of Early Response to Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
por: Ferrucci, Silvia, et al.
Publicado: (2023) -
Asthma improvement in patients treated with dupilumab for severe atopic dermatitis
por: Dubini, Marco, et al.
Publicado: (2023) -
Emerging Systemic Treatments for Atopic Dermatitis
por: Ferrucci, Silvia Mariel, et al.
Publicado: (2023)